A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Conditions

• Type 2 Diabetes

Eligibility Criteria

Sex

ALL

Age

10 Years - 17 Years

Healthy Volunteers

Not accepted

Interventions

• Dulaglutide — DRUG
  Administered SC

Study Details

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

Key Dates

Start date

Jan 10, 2025

Status verified

May 2026

Primary completion

Dec 31, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

55 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Dulaglutide
  Participants will receive dulaglutide subcutaneously (SC)

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Week 26 ]

Central Contacts

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  1-317-615-4559
  [email protected]
• Physicians interested in becoming principal investigators please contact
  [email protected]

Locations (41)

Find similar trials in Tucson, AZ

Related Studies

• Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
  PHASE1/PHASE2 · Not Yet Recruiting · ARKAY Therapeutics · Albany, New York
• The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
  Recruiting · AdventHealth Translational Research Institute · Orlando, Florida
• Sleep and Glycemic Control in Type 2 Diabetes Adolescents
  Recruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
• Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)
  Recruiting · Children's Hospital Los Angeles · Los Angeles, California